Famotidine: Pharmacodynamic and Pharmacokinetic Properties and a Preliminary Review of its Therapeutic Use in Peptic Ulcer Disease and Zollinger-Ellison Syndrome

Drugs

Volumn 32, Issue 3, 1986, Pages 197-221

  Campoli Richards, Deborah M ^a   Clissold, S P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDIAZEPOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DIAZEPAM; FAMOTIDINE; GEFARNATE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOCYANINE GREEN; KETOCONAZOLE; MIDAZOLAM; OMEPRAZOLE; PENTAGASTRIN; PHENAZONE; PHENYTOIN; PLACEBO; PROCAINAMIDE; PROPRANOLOL; RANITIDINE; TETRACYCLINE; THEOPHYLLINE; WARFARIN;

ADVERSE DRUG REACTION; AUDITORY SYSTEM; CARDIOVASCULAR SYSTEM; DIGESTIVE SYSTEM; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG COMPARISON; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DUODENUM ULCER; FACE EDEMA; FAMOTIDINE C 14; FATIGUE; FLUSHING; GASTRIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INTOXICATION; KIDNEY; NERVOUS SYSTEM; NEUROTOXICITY; PERIPHERAL VASCULAR SYSTEM; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE; STOMACH; STOMACH ACID SECRETION; STOMACH ULCER; SURVEY; TINNITUS; ZOLLINGER ELLISON SYNDROME;

ANIMAL; FAMOTIDINE; HISTAMINE H2 ANTAGONISTS; HUMAN; KINETICS; PEPTIC ULCER; THIAZOLES; ZOLLINGER-ELLISON SYNDROME;

EID: 0022466846     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198632030-00001     Document Type: Article

References (135)

1. Famotidine in the management of duodenal ulcer: experience in Italy
2. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders
3. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience
4. 2-receptor antagonists on the mouse isolated stomach assay
5. Pharmacokinetics of cimetidine after single doses and during treatment
6. Pharmacokinetics and bioavailability of ranitidine in humans
7. An investigation of the effect of oral ranitidine treatment of hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal function in male and female volunteers
8. 2-receptory antagonist: summary of preclinical safety assessment
9. Clinical and endocrine aspects of treatment with ranitidine
10. Effects of cimetidine and ranitidine on hepatic drug metabolism
11. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases
12. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease
13. Antiandrogen effect of cimetidine in mice
14. Famotidine: summary of preclinical safety assessment
15. 2-receptor antagonist in healthy man
16. Comparison of cimetidine 800mg once daily and 400mg twice daily in acute duodenal ulceration
17. A high performance liquid chromatography method for the determination of ranitidine in plasma
18. A method for the determination of ranitidine and its metabolites in urine by HPLC and its application to study the metabolism and pharmacokinetics of ranitidine in man
19. Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography
20. Famotidine does not interfere with the disposition of theophylline in man
21. Beschleunigte Heilung des Ulcus ventriculi unter einer abendlichen Einzeldosis von Famotidin
22. Effect of intravenous famotidine and ranitidine on intragastric pH and hormone levels in critical care patients. 5th International Conference on Experimental Ulcer
23. 2-blockers
24. 2-Blockern
25. Famotidine: nocturnal dosing for gastric ulcer healing
26. Cimetidine once daily
27. Cimetidine 800mg nocte in the treatment of acute duodenal ulceration
28. 2-receptors in man
29. Decreased oral warfarin clearance after ranitidine and cimetidine
30. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man
31. Cimetidine impairs the clearance of an orally administered high clearance drug, chlormethiazide
32. 2-receptor blockers
33. Toxicological studies on omeprazole
34. Ranitidine influences uptake of oral midazolam
35. Is the measurement of blood cimetidine levels useful?
36. 2-blockers, ranitidine and famotidine on nocturnal gastric pH: computer evaluation
37. IV famotidin versus IV ranitidin: Intragastrales pH-Verhalten bei chirurgischen Intensivpatienten
38. 2-receptor antagonist, occupies androgen receptors
39. Multiclinic double-blind dose ranging study evaluating the efficacy and safety of famotidine in the healing of active duodenal ulcer as compared to placebo
40. Prolactin behaviour during long-term Famotidine treatment in man
41. Bioavailability and pharmacokinetics of cimetidine
42. Cimetidine plasma concentration-response relationships
43. 2-sulfamoylpropionamidine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pig
44. Parietal cell vagotomy or cimetidine maintenance therapy for duodenal ulcer
45. Properties of famotidine in relation to safety
46. Effect of cimetidine on endocrine function — prolactin
47. 2-receptor antagonists on hepatic drug metabolism
48. Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism
49. Cimetidine interaction with phenytoin
50. Famotidine (MK 208) in the treatment of duodenal ulcer: short term multicentre studies and a maintenance trial
51. 2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome
52. 2-receptor antagonists for duodenal ulcer
53. 2-receptor blocker, in man
54. Ranitidine 150mg twice daily vs 300mg nightly in treatment of duodenal ulcers
55. Effects of antiulcer agents on healing of mepirizole-induced duodenal ulcers in rats
56. 2-receptor antagonist: absorption, distribution, metabolism and excretion in rats
57. 2-receptor antagonist: absorption and excretion in dogs and humans
58. Interactions and non-interactions with ranitidine
59. 2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide
60. Delayed clearance of diazepam due to cimetidine
61. Single daily dose of cimetidine for the treatment of symptomatic duodenal ulcer: results of a comparative two-centre clinical trial
62. Traitement de l’ulcère duodénal par une dose unique nocturne de cimétidine: étude multicentrique conduite dans 12 centres hospitaliers Français
63. Antisecretory drugs and gastric cancer
64. Ranitidine kinetics and dynamics
65. 2-receptors on fentanyl metabolism
66. 2-receptor antagonist
67. 2-receptor antagonists
68. 2-receptor inhibitor, MK-208. Abstract
69. 2-receptor antagonist ranitidine in man
70. Physiological factors that modify systemic drug availability and pharmacologic response in clinical practice
71. Cimetidine once daily
72. 2-antagonist, YM-11170, in healthy subjects
73. Clinical study on the efficacy and safety of famotidine in acute gastric ulcers
74. Famotidine: summary of overall safety from Japanese clinical studies
75. Comparison of famotidine and gefarnate in the treatment of gastric and duodenal ulcer
76. Dose-finding study of famotidine in peptic ulcers
77. Clinical evaluation of famotidine (YM-11170) for duodenal ulcer: a double-blind comparison with cimetidine
78. Clinical evaluation of famotidine for gastric ulcer: comparison with cimetidine by double-blind method
79. Study of the usefulness of famotidine in the treatment and prevention of recurrences of peptic ulcer
80. 2-Blockern
81. Famotidine (MK-208): duration of action, 24-hour intragastric acidity, antipyrine kinetics and basal hormone levels. Abstract
82. 2-receptor antagonist, famotidine (YM-11170) on gastric acid secretion
83. 2-receptor antagonist, famotidine (YM-11170), on gastric acid secretion
84. Clinical pharmacology of famotidine: effect of famotidine on gastric secretion
85. 2-receptor antagonist, on gastric secretion and gastric and duodenal lesions in rats
86. Famotidine (MK-208) in the treatment of gastric ulcer: results of a multicenter double-blind controlled study
87. Comparative trial of 400mg cimetidine twice daily and 1000mg daily in the short-term treatment of duodenal ulceration
88. 2-receptor antagonist: radioreceptor assay for antiandrogen side effects
89. 2-receptor blocking drugs on basal levels of gonadotrophins, prolactin, testosterone and oestradiol-17B during treatment of duodenal ulcer in male patients
90. Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon
91. 2-receptor antagonist
92. 2-antagonist drug interactions in perspective: mechanistic concepts and clinical implications
93. Effect of cimetidine on microsomal drug metabolism in man
94. Interaction of cimetidine with liver enzymes
95. Cimetidine impairs the elimination of theophylline and antipyrine
96. Mehrjährige Rezidivprophylaxe der pertischen Ulkuserkrankung mit 400mg Cimetidin zur Nacht
97. Inhibition of nocturnal gastric acid secretion by famotidine
98. Effect of dose size, frequency and timing of famotidine (MK-208) on nocturnal and meal-stimulated gastric secretion
99. Clinical pharmacology of famotidine: summary of data from the United States
100. Influence of famotidine and cimetidine on the disposition of phenytoin and indocyanine green
101. 24-hour intragastric acidity in duodenal ulcer patients after oral administration of a single dose of famotidine
102. Effects of hormones (calcitonin, GIP) and pharmacological antagonists (ranitidine and famotidine) on isolated rat parietal cells
103. Cimetidine: interaction with oral anticoagulants in man
104. 2-receptor antagonism of MK-208 in isolated rabbit gastric glands
105. Famotidine versus ranitidine in the short-term treatment of duodenal ulcer: a double-blind randomized multicentre study in Germany
106. Famotidine versus ranitidine for the short-term treatment of duodenal ulcer
107. 2-receptor inhibitor
108. 2-receptor antagonist, MK-208, on gastric parietal and nonparietal secretion. Abstract
109. 2-receptor antagonist: effect on parietal, nonparietal and pepsin secretion in man
110. Drug interactions with cimetidine
111. Cimetidine clearance and bioavailability in hepatic cirrhosis
112. Influence of ranitidine on plasma metoprolol and antenolol concentrations
113. Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers
114. Untersuchungen zur Wirkung von Ranitidin auf den Antipyrin-Metabolismus
115. Pharmacokinetics of famotidine in patients with renal insufficiency
116. 2-receptor antagonist, in relation to renal function
117. 2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs
118. 2-blocker, famotidine (YM-11170)
119. Therapeutic effect of famotidine (YM-11170) on peptic ulcers
120. 2-antagonist, YM-11170, in conscious dogs
121. 2-antagonist, YM-11170 in anesthetized dogs and isolated guinea-pig ileum
122. 2-sulfamoyl propionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats
123. 2-receptor antagonist on in vivo immediate and delayed type hypersensitivity reactions and antibody formation
124. Double-blind, crossover comparison of the effects of ranitidine and cimetidine on hepatic drug metabolism in healthy volunteers
125. 2-receptor blocker, in plasma and urine
126. Effects of cimetidine and ranitidine on gastric transmural potential difference and on prolactin secretion in man
127. Bioavailability of cimetidine in man
128. Comparison of ranitidine and cimetidine maintenance treatment of duodenal ulcer
129. Investigation on the penetration of ranitidine into the cerebrospinal fluid and a comparison of the effects of ranitidine on male sex hormones
130. Cimetidine: a clinical and pharmacokinetic study
131. Assessing the safety of drugs for the long-term treatment of peptic ulcers
132. Therapeutic effects of a single daily administration of 40mg famotidine at bedtime to cases of peptic ulcers